Influenza infections are initiated by the binding of the influenza hemagglutinin (hA) and the cellular receptor sialic acids. the binding is followed by internalization, endocytosis, and uncoating to release the influenza genome to the cytoplasm. It is conceivable that specific inhibitors that antagonize any one of these events could prevent the replication of influenza infections. the authors made hA pseudotyped retroviral vectors that express luciferase reporter activities upon transduction to several recipient cells. the transduction of the hA-pseudotype virus particles (hApp) was mediated through the specific interactions between an avian hA and the terminal disaccharides of sialic acid (SA) and galactose (gal) in α-2,3 linkage. the hApp-mediated transduction method was used to develop a high-throughput screening assay and to screen for hits from a fermentation extract library. Specific hits that inhibited the hA-mediated but were noninhibitory to the vesicular stomatitis virus-mediated pseudoviral transductions were identified. A few of these hits have anti-influenza activities that prevent the replication of both h1n1 (WSn) and h5n1 (Rg14) influenza viruses. (Journal of Biomolecular Screening 2009:294-302) 
INTRODUCTION

I
nfluenzA viRuSeS BelOng tO the ORthOmyXOvIRIDAe family viruses and are pathogens for humans and animals. there are 3 types of influenza viruses: influenza A, B, and C. Influenza A is the most virulent one that can be classified to many subtypes based on the surface glycoproteins of hemagglutinin (hA) and neuraminidase (nA). there are 16 hA and 9 nA subtypes of influenza A, and any one influenza strain has one of the hA and nA subtypes. the different surface glycoprotein subtypes, the rapid mutation of the virus genes, and the mixing of genetic pools by migratory birds have contributed, at least partially, to the persistence of this old pathogen.
1,2 the continued evolution and spreading of the highly pathogenic h5n1 avian influenza strains that initially appeared in hong Kong in 1997 suggest that influenza infections will probably remain a potential health threat for human beings. 3, 4 Influenza is a negative-strand segmented RnA virus with 8 RnAs that code for 11 proteins. Both hemagglutinin and neuraminidase interact with the terminal sialic acids of glycoproteins and glycolipids and are responsible for initiating infection and releasing progeny influenza viruses, respectively. the interaction between the influenza hA and sialic acid is the most well-established receptor-ligand interaction among all viruses. hemagglutinin is synthesized as hA0, which is subsequently cleaved to hA1 and hA2 by cellular proteases. hA1 is responsible for sialic acid binding, and hA2 undergoes low ph-mediated conformational change, causing membrane fusions and releasing the influenza genome to the cytoplasm. 5, 6 hA from avian influenza binds α-2,3 Siagal, whereas the hA from human influenza viruses preferentially binds α-2,6 Siagal. these binding preferences are consistent with the infection tropisms of these 2 viruses. [7] [8] [9] [10] Avian influenza viruses infect avian species at the enteric tracks that have α-2,3 Siagal as the predominate form. In contrast, human influenza viruses infect respiratory tracks where the α-2,6 Siagal forms are most prominent at the upper respiratory tissues and the α-2,3 Siagal structures are found mainly at the lower respiratory tissues. 11, 12 Our primary defense for the seasonal influenza infections is through annual vaccinations. At this time, there are no vaccines for the putative pandemic avian influenza infections. four antiinfluenza drugs targeting the m2 protein (amantadine and rimantadine) and the neuraminidase (tamiflu and Relenza) are available for treatments.
13-15 the m2 protein functions as an ion channel that permits ions to enter endocytosed virions and to modulate ph in intracellular compartments. the m2 inhibitors are effective only for influenza A; they are ineffective against the influenza B infections. 16 In addition, amantadine-resistant influenza mutants exist either naturally in some of the avian influenza strains or are rapidly developed after a short period of treatments. 17 the primary function of influenza neuraminidase is to cleave cellular and viral sialic acids that interact with viral hemagglutinin proteins, preventing the release of progeny viral particles. Both tamiflu and Relenza are effective neuraminidase inhibitors and prevent influenza replication at nm concentrations in vitro. Influenza mutants resistant to neuraminidase inhibitors also were reported 14, 18 in clinical as well as in laboratory strains. to prepare for possible pandemic influenza infections due to avian influenza viruses, we need additional anti-influenza agents inhibiting virus replication at different targets.
We recently reported the use of the hA-pseudotyped retroviral vectors that express influenza surface hA protein on the retroviral framework and carry reporter luciferase to model the influenza viral release events. the release assay was quantitative and was used to evaluate the potencies of neuraminidase inhibitors under physiological conditions. 19 this report describes the use of the hA-pseudotyped virus particles (hApp) to model the hA-mediated infection to target cells using a convenient transduction assay. the hA-mediated transduction assay was used to screen for inhibitors; some of the inhibitor hits were found to be active as antiviral agents, preventing influenza replications.
MATERIALS AND METHODS
Viruses, cells, and reagents
Influenza A/WSn/1933 (h1n1) (from Dr. Shin-Ru Shih, Chang gung university, taiwan) was cultured in the allantoic cavities of 10-day embryonated chicken eggs for 72 h, harvested, and purified by sucrose gradient centrifugation. Recombinant h5n1 influenza Rg14 (from Dr. Jia-tsrong Jan, genomic Research Center, Academia Sinica, taiwan) was cultured in madin-Darby canine kidney (mDCK) cells for 72 h and passed through 0.45-µm filters. Influenza titers were determined by plaque-forming units (see below) or by tCID 50 (50% tissue culture infectious dose). tCID 50 was determined using 1 × 10 5 cells/ ml mDCK cells and serially diluted influenza virus stock, and it was calculated using the Reed-muench method. 20 the cytopathic effects on infected cells were determined using Celltiter 96  AQueous non-Radioactive Cell Proliferation Assay reagent from Promega (madison, WI).
mDCK and 293t cells were obtained from American type Culture Collection (manassas, vA). the human alveolar epithelial cell A549 and the human large-cell carcinoma h460 cells were gifts from Drs. King-Song Jeng and Alice yu, Academia Sinica, respectively. All cells were grown in Dulbecco's modified eagle's medium (Dmem) containing 10% fetal bovine serum (fBS) and penicillin-streptomycin at 37 °C under 5% CO 2 . Peptides eB (RRKKAAvAllPAvllAllAPg) and eBX (RRKKlAAlPlvlAAPlAvlA) 21 were synthesized using ABI 443A peptide synthesizer (Applied Biosystems, foster City, CA). Influenza neuraminidase used in the study was prepared as described previously. 19 Recombinant hA from A/vietnam/1203/h5n1 was purchased from Protein Science Corporation (meriden, Ct).
the fermentation extract library was obtained from Panlab Corporation (taipei, taiwan). the extracts were secondary metabolites prepared from different Actinomycetes strains cultured under 4 different growth conditions. the ethyl acetate extracts of the entire cultures were dried down and redissolved in DmSO and used at 1% final concentration for highthroughput screening (htS).
Plasmid constructions
Plasmids phA and pnA are derivatives of pcDnA3.1 (Invitrogen, Carlsbad, CA) expressing hA (A/vietnam/1194/2004, genBank ef541402) 22 and nA proteins (A/WSn/1933 tS61, genBank Cy010790). the plasmid pvSv expressing vesicular stomatitis virus (vSv) glycoprotein was a gift from Dr. KingSong Jeng, Academia Sinica. the mulv retrovirus expression system pgagPol(mulv) and the retrovial plasmid pCnCl(mlvfluc) expressing reporter firefly luciferase were reported previously. , and 50 µl transItlt1 transfection Reagent (mirus, houston, tX) and replenished with fresh media after an overnight incubation. the conditioned media were harvested after 2-day incubations, filtered through 0.45-µm filters, and either used immediately or frozen at -80 °C as the hA-pseudotyped mulv (hApp) or vSvpseudotyped mulv (vSvpp) preparations. the hA contents of hApp preparations were determined by enzyme-linked immunosorbent assay (elISA; BioAssay Systems, hayward, CA) and found to be in the range of 3 to 5 µg hA per ml hApp. the amounts of hApp used were defined as units; 1 unit was equivalent to hApp with 0.1 µg hA. luciferase activities were measured using the Britelite assay kit and read with envision (Perkinelmer, Waltham, mA).
Pseudotyped virus entry inhibition assay
for kinetic studies of hApp transduction, cells of A549, h460, mDCK, and 293t were used for comparisons. these cells were seeded to 96-well plates at 1 × 10 4 cells/well. After an overnight incubation, 4 units of hApp were added to the wells and incubated for varied incubation times. the unbound hApp was removed by washing with phosphate-buffered saline (PBS) 3 times. After additional incubation for 48 h, cells were lysed to determine the luciferase activities (4 repeats), to measure the extent of hApp transduction.
twelve thousand 293t cells in 50 µl Dmem, 2% fBS were seeded onto the wells of 384-well plates 1 day prior to transduction. testing samples at varied concentrations and 2 units of hApp were added to each well and incubated for 2 days. variations of the transduction conditions were tested. When 1 unit of hApp was used, a reduced signal-to-noise ratio resulted (coefficient of variation [Cv] >10%). Incubation for 3 days after transduction was also tried, and variation of well drying at the edges of the plate occurred. luciferase activities were measured after incubation with Britelite according to the manufacturer's instructions, and the readings were taken by viewlux (Perkinelmer). the IC 50 values of inhibitors were determined by curve fitting using graphPad Prism (graphPad, la Jolla, CA).
Preparation of oligosaccharides and sugar array binding assays
Sialyl disaccharides and trisaccharides were prepared using synthetic procedures as described. [24] [25] [26] the synthetic oligosaccharides were further modified to cross-link to glass surface for the preparation of "sugar arrays" as previously reported. 27 to detect the binding to sugar arrays, we used the hA antibody, B88240R, from meridin life Sciences (memphis, tn) and the Cy3-labeled second antibody from Jackson ImmunoResearch lab (West grove, PA). the image of the bound hApp was captured by Axon gene Pix 4400A from molecular Devices (Sunnyvale, CA).
Anti-influenza infectivity assays
the dose-dependent anti-flu activities of inhibitors were shown by the protection of the influenza virus-mediated cytopathic activities. ten thousand mDCK cells were plated onto the wells of 96-well plates 1 day prior to infection. testing inhibitors at varied concentrations in 100-µl infection medium (Dmem, 2% fBS, with 100 tCID 50 h1n1 [WSn]) were added to mDCK cells. After incubation at 37 °C for 48 h, the cytopathic effects were determined with Celltiter 96  AQueous non-Radioactive Cell Proliferation Assay reagent (Promega). A similar procedure was used to show the anti-influenza activity against the h5n1 virus, except the infective medium was serum-free Dmem containing 2 µg/ml tPCK-trypsin and 100 tCID 50 h5n1 (Rg14). the anti-influenza activities of hits were also measured to determine the inhibition of influenza virus yields. Diluted influenza virus preparations were incubated in Dmem with 10% fBS with different inhibitor concentrations. After a 1-day incubation, influenza yields were determined from treated samples by counting the number of plaqueforming units of fixed and crystal violet-stained mDCK cells.
RESULTS AND DISCUSSION
HApp transduction assay to model influenza early infection events Figure 1 shows the procedure for the production of hApp and the use of the produced hApp to study the hA-mediated transduction using luciferase expression as a reporting system. upon transfection with 4 plasmids to synthesize the influenza hA, nA, the reporter RnA for luciferase, and retroviral gag and polymerase proteins, hApp is produced and discharged to the conditioned media of 293t cells. the produced pseudotyped virus particles contain the RnA of the reporter luciferase that is used to report the transduction activity. the hApp-mediated transduction could be used to model the influenza virus early infection events, including entry, endocytosis, and uncoating. the hApp preparations were tested on 4 cell lines: 293t, A549, h460, and mDCK cells. All 4 cells can be transduced for the expression of the luciferase reporter, and the hApp entry to these cells was time dependent and reached saturation after incubation for 2 to 5 h (Fig. 2) .
Requirements for HApp transduction
the initiation of the influenza infection requires the interaction of the influenza hA and the cellular sialic acid receptors. We investigate the role of sialic acids on hApp transduction by comparing the ability to receive hApp between the neuraminidasedesialylated 293t cells and the mock-treated 293t cells. the neuraminidase-treated 293t cells were poor recipient cells for hApp transduction, suggesting that sialic acid-containing receptors are required for hApp entry (Fig. 3A) . the hA used for the preparation of hApp was from avian influenza A/vietnam/1194/2004/h5n1. the hApp thus produced is expected to interact preferentially to Sial-α-2,3-gal. to evaluate this specificity, we added oligosaccharides of Sial-α-2,3-gal or Sial-α-2,6-gal, along with hApp, to compete for binding and transduction to 293t cells. the hApp transduction was inhibited specifically by Sial-α-2,3-gal at 5 mm. treatment with Sial-α-2,6-gal at the same concentration did not inhibit the hApp entry (Fig. 3B) . In addition to the characterization of the interaction between hApp and sialic acids using cell-based entry assays, we also used immobilized sialic acid analogs as "sugar arrays" to study the binding of hApp to 3 different oligosaccharides (Fig.  4A) . Binding to the immobilized sugar was highly specific; the recombinant avian hemagglutinin from A/vietnam/1203/ h5n1 bound specifically only to disaccharide, Sial-α-2,3-gal and trisaccharide, Sial-α-2,3-gal-β1,4-glcnAc and not to Sial-α-2,6-gal. Similarly, hApp expressing avian hA from A/ vietnam/1194/h5n1 had the same binding specificity only to Sial-gal with α2,3 linkages (Fig. 4B) . these results suggest that the hApp-mediated transduction had similar specificity of the influenza infection, and the hApp transduction assay is thus a reasonable model for the early events of influenza infection. Figure 2 show that all 4 tested cells can be transduced by hApp with a similar time course of hApp entry. upon hApp transductions, 293t cells produced higher luciferase activities. We also showed that 293t cells are susceptible to h5n1 (Rg14) infection by the appearance of cytopathic effects shortly after incubation with Rg14 (data not shown). the 293t cells were thus used for htS assay development studies. two methods to transduce 293t cells were tested for the development of an htS assay. One method was to mix trypsinized 293t cells with hApp and then dispense the mixture to wells. the other method was to add hApp to preseeded 293t cells. the first method, although faster and simpler, usually resulted in larger Cv, whereas the second method often produced 10% or smaller Cvs. to ensure consistency in hApp qualities, we made hApp preparations in several large preparations and pooled and stored them at -80 °C. the crude hApp preparations were made by filtration of the conditioned medium using 0.45-µm filters. Purified hApp by ultracentrifugation was also prepared for comparison. We found that crude and purified hApp produced similar Cv under the screening conditions; thus, crude hApp was used for assay developments. We found that the additional step to remove hApp after incubation usually resulted in larger Cvs. to simplify the htS development, we did not remove hApp in incubation time. the effects of DmSO at different concentrations were tested, and at 1% or lower concentrations, DmSO had no inhibitory effects on the transduction results. varied numbers of 293t cells were seeded in 384-well microplates and used for hApp transductions. Figure 5A shows fairly even luciferase reporter expressions, with Cv values of 8% and 9.2% in assays using 20,000 or 10,000 cells per well; the Cv value for wells with 5000 cells was 12%. z′ values were used to assess the signal-to-background ratios of the results obtained from the 3 cell densities versus that from the no-cell control. the calculated values were 0.70, 0.67, and 0.28, indicating that good signal to noise can be obtained in assays with more than 10,000 cells per well. We used the peptide eB as the inhibitor control for assay developments. eB is a novel 20-amino acid antiviral peptide derived from the signal sequence of fibroblast growth factor 4 and has been shown to bind hemagglutinin and inhibit influenza attachment to recipient cells. 21 We tested the inhibitory activity of eB to hApp entry at several concentrations. As a negative inhibitor control, the sequence-scrambled peptide, eBX, was also tested at similar concentrations. Figure 5B shows that eB inhibited hApp transduction with an IC 50 of 9 µm, much more potent than the control peptide eBX. Antiviral activities of these 2 peptides were also examined. the anti-influenza activity of eB against WSn had an estimated IC 50 of 35 µm, comparable to the reported activities against h1n1 influenza viruses. 21 the inhibition of hApp transduction by eB provided an additional support that the hApp transduction assay is a model mimicking the hA-mediated influenza infection to recipient cells.
Development of an HTS assay for HApp transduction inhibitors the results in
HTS for HApp transduction inhibitors
the possibility of using the hA-pseudotyped vector for screening influenza antagonists was evaluated using a fermentation extract library with about 10,000 samples. the screening was done in a 384-well format by seeding 293t cells at 12,000 cells per well 1 day before the screening. Cells in microwell plates were added with individual testing samples and followed immediately with 2 units of hApp per well. the inhibitions of the testing samples to hApp transductions were evaluated by examination of the expressed luciferase activities after incubation for 2 days. two controls were incorporated into each assay plate. the negative control wells contained no cells to guard against possible false luciferase activities due to the presence of luciferase-expressing cells that contaminated the hApp preparations. In addition, 2 columns of wells contained 293t cells and hApp, but no testing samples served as positive controls. In a few assay plates, eB at 30 µm was added to wells as inhibitor controls to demonstrate the expected inhibitions.
the calculated z′ values between the positive and negative controls are 0.62, and those between the positive and inhibitor controls are 0.52. A scatterplot of data points from plates with positive, negative, and eB (30 µm) controls is shown in Figure  6A . the majority of the data points are scattered within 1 standard deviation of the mean of the positive control value. the primary hits (770 hits with a hit rate of 5%) were collected from samples that had lower than 33% mean luciferase activity of the positive control values. most of these hits were cytotoxic and were confirmed in separate assays on 293t cells. those hits that were noncytotoxic to 293t cells were subjected to a secondary assay resulting in the identification of 8 specific inhibitors that were inhibitory to the hApp-mediated and were noninhibitory to the vSvpp-mediated transductions to 293t cells. One specific inhibitor, fermentation extract gRC186, inhibited the hApp-mediated transduction at concentrations about 100-fold lower than that for the vSv-mediated transduction (Fig. 6B) .
Anti-influenza activities of HApp transduction inhibitor GRC186
the anti-influenza activity of gRC186 was examined on both the h1n1 (WSn) and the h5n1 (Rg14) influenza A strains. Both influenza strains caused cytopathic effects on mDCK cells that have been used as the standard cells for influenza studies. the anti-influenza activity of gRC186 was tested at several concentrations and demonstrated concentrationdependent protection from the influenza-mediated cytopathic effects (Fig. 7A) . the inhibitory activity of gRC186 on influenza replication was also confirmed by examining the reduction of influenza plaque-forming units from infected cultures that were treated with different gRC186 concentrations (Fig. 7B) .
to our knowledge, this report is the first study using the hApp transduction to model the early events of influenza infection, including hA-sialic acid interaction, endocytosis, and uncoating to release the influenza RnAs. the hApp that expresses avian hA interacted with Siagal disaccharides with α-2,3 linkages consistent with the avian influenza infection tropism. We used the hApp to develop a simple and safe protocol for an htS assay for transduction inhibitors. the htS assay was used to screen a fermentation extract library and resulted in specific inhibitors that prevented the hApp-mediated transduction and were active in inhibiting influenza virus replications. Among the noncytotoxic hits, some were inhibitory to the transduction of both hApp and vSvpp. these falsepositive hits could be inhibitory to common elements of both pseudotype viruses, such as binding, entry, or uncoating. We do not know the active components in the extract gRC186 that are responsible for the transduction inhibition. large quantities of the fermentation extract of gRC186 will be prepared for the isolation and structural determination of the active component responsible for the influenza inhibition. the isolated compound will then be used to evaluate in vivo anti-influenza efficacy, targeting cells, and inhibition mechanisms. 
